Sevelamer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hyperphosphataemia in patients with chronic renal failure has traditionally been treated with calcium- and aluminium-containing phosphate binders. This article briefly discusses the rationale and complications of these treatments and reviews sevelamer that is a novel non-calcium-, non-aluminium-containing phosphate binder and the evidence to support its use in clinical practice.

Related collections

Most cited references 2

Record: found
Abstract: not found
Article: not found

Dialysis therapy.

S Pastan, J Bailey (1998)

0 comments Cited 22 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder.

M Gallieni, M Cozzolino, D Brancaccio (2000)

0 comments Cited 5 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (publisher-id): NEC

Journal ID (nlm-ta): Nephron Clin Pract

Journal ID (doi): 10.1159/issn.1660-2110

Title: Nephron Clinical Practice

Publisher: S. Karger AG

ISSN (Electronic): 1660-2110

Publication date Subscription-year: 2003

Publication date (Print): July 2003

Publication date (Electronic): 17 November 2004

Volume: 94

Issue: 3

Pages: c53-c58

Affiliations

Oxford Kidney Unit, Churchill Hospital, Oxford, UK

Article

Publisher ID: 72021 Other ID: Nephron Clin Pract 2003;94:c53–c58

DOI: 10.1159/000072021

PubMed ID: 12902631

SO-VID: aa83a65d-c9f8-429a-8386-854a7917f61f

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Page count

Figures: 1, Tables: 1, References: 20, Pages: 1

Comments

Comment on this article

scite_

Cited by 1

Pi-induced in-situ aggregation of sevelamer nanoparticles for vascular embolization
Authors: Qiu-chen Bi, Yan-shu Li, Rong-guang Luo …

See all cited by

Most referenced authors 58

See all reference authors

Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

Submit here before December 31, 2024